IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3670
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$217M
Rachel E. Haurwitz
Caribou Biosciences, Inc. engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010 and CB-011, which are in phase 1 clinical trials to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CRBU Caribou Biosciences, Inc. | 39 | 35 | 23 | 43 | - | - | -110.2% | -80.2% | 100.0% | -1708.6% | -1673.7% | -36.5% | 0.0% | 37.0x | $217M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Caribou Biosciences, Inc. (CRBU) receives a "Avoid" rating with a composite score of 39.0/100. It ranks #3670 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CRBU.
View All RatingsROE proxy -110.2% (sector -1.9%)
GM 100% vs sector 44%, OM -1709% vs sector 3%
Capital turnover N/A, R&D intensity 1186.3%
Rev growth -37%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Caribou Biosciences, Inc. (CRBU) as Avoid with a composite score of 39.0/100 at a current price of $2.20. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Caribou Biosciences, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 39.0/100 places it at rank #3670 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 100% signal strong pricing power.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Caribou Biosciences, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Caribou Biosciences, Inc. with an Avoid rating, assigning a composite score of 39.0/100 and 1 out of 5 stars. Ranked #3670 of 7,333 stocks, CRBU falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CRBU's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -110.2% (sector avg: -1.9%), gross margins of 100.0% (sector avg: 44.1%), net margins of -1673.7% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
CRBU registers a value score of just 23/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.19x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Caribou Biosciences, Inc.'s investment score of 28/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -36.5% vs. a sector average of 6.7% and a return on assets of -80.2% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CRBU is currently showing below-average momentum at 43/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -36.5% year-over-year, while a beta of 1.67 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
CRBU's stability score of 36/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.67 and a debt-to-equity ratio of 37.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Caribou Biosciences, Inc.'s short interest score of 22/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.67), elevated leverage (D/E: 37.00x), micro-cap liquidity risk. At $217M (micro-cap), CRBU carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Caribou Biosciences, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3670 of 7,333 overall (50th percentile). Key comparisons include ROE of -110.2% trailing the -1.9% sector median and operating margins of -1708.6% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CRBU currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (22) would have the largest impact on the composite score.
ROE 5701% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 127% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 68173% BELOW SECTOR MEDIAN
Clear Street has initiated coverage on Caribou Biosciences Inc. (NASDAQ:CRBU) with a Buy rating and a $13.00 price target, citing optimism about the biotech company's off-the-shelf allogeneic CAR-T cell therapies. The firm believes Caribou's therapies offer strong efficacy, durability, and a lower manufacturing burden, with the stock currently trading near cash levels. Recent positive clinical trial data for its CAR-T programs vispa-cel and CB-011 further support the positive outlook.
Caribou Biosciences (NASDAQ: CRBU) will host a KOL panel event at the 67th ASH Annual Meeting on December 6, 2025, to discuss vispa-cel, their allogeneic anti-CD19 CAR-T cell therapy. The session will focus on how vispa-cel can expand access to second-line large B cell lymphoma care in both community and academic settings. Moderated by Tina Albertson, MD, PhD, the event will feature leading clinicians from various institutions.
Caribou Biosciences reported positive Phase 1 trial data for CB-011 in relapsed or refractory multiple myeloma, showing a 92% overall response rate and 91% MRD negativity at the recommended expansion dose. Dose expansion is planned to start by year-end 2025, with data expected in 2026. The therapy has a manageable safety profile and is considered a potential best-in-class allogeneic CAR-T cell therapy.
Caribou Biosciences (NASDAQ: CRBU) will host a webcast on November 3, 2025, to present new clinical data from two allogeneic CAR-T cell therapy programs: updated results from the ANTLER Phase 1 trial of vispa-cel in B cell non-Hodgkin lymphoma, and the first clinical data from the CaMMouflage Phase 1 trial of CB-011 in multiple myeloma. The company will also detail its anticipated pivotal Phase 3 trial design for vispa-cel and outline next steps for CB-011 development. The webcast will be available live and archived on Caribou's Events page.
Caribou Biosciences, Inc. (Nasdaq: CRBU) will host a webcast on Monday, November 3, 2025, to present new data from two allogeneic CAR-T cell therapy programs. This webcast will cover updates from the ANTLER Phase 1 clinical trial for vispacabtagene regedleucel (vispa-cel) in B cell non-Hodgkin lymphoma and introduce the first clinical data for CB-011 in multiple myeloma from the CaMMouflage Phase 1 trial. The company will also discuss the anticipated pivotal Phase 3 trial design for vispa-cel and future development plans for CB-011.
Above 50MA
37.18%
Net New Highs
+51081